Literature DB >> 4708458

Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study.

H Oosterhuis, J Bethlem.   

Abstract

An investigation was made into the occurrence of muscular atrophy and muscular pathology in a series of 170 patients with myasthenia gravis. The results can be summarized as follows: (1) Of the 148 patients with generalized myasthenia gravis, 14 showed local muscular atrophies. Of 10 biopsies from atrophic muscles, eight showed neurogenic changes, with or without lymphocytic infiltrations. One biopsy showed lymphocytic infiltrations only, and one showed type II-fibre atrophy (Table 1). No relationship was demonstrable between the presence of clilnical muscular atrophy and age, sex, duration of the disease, severity of the disease, presence of a thymoma, or drug resistant ophthalmoplegia. (2) In this group of patients 61 biopsies were examined from 46 individuals; 40 of these biopsies were taken from the quadriceps muscle. A thymoma was present in 17 patients. Examination disclosed neurogenic changes in 17 biopsies, lymphocytic infiltrates in 21, and myositis in one biopsy (Table 2). A distinct correlation was established between the presence of a thymoma and lymphocytic infiltrates, but none was demonstrable between thymoma and neurogenic changes (Table 3). (3) An enzyme-histochemical study was carried out in 35 cases, including 12 with neurogenic changes. A normal differentiation of type I- and type II-fibres was observed in eight instances, type grouping of type II-fibres in three, and type II-fibre atrophy in two cases. (4) In 21 patients and 19 controls, the smallest mean diameter was determined in the quadriceps muscle. Both type I- and type II-fibres proved to have a smaller mean diameter in the female patients than in the controls. In the male patients this could not be proven. (5) Of the eight patients who had died without disorders of ventilation, 90 muscle specimens were examined postmortem. Four of these patients had a thymoma. Lymphocytic infiltrations, found in 32 biopsy specimens, were mostly observed in the presence of a thymoma. Neurogenic changes were apparently unrelated to the presence of a thymoma (Tables 5 and 6). The post mortem examination included the spinal cord in five, and peripheral nerves in three cases. No abnormalities were found. (6) The muscular atrophy found in patients with myasthenia is not a myopathy but an affection of the lower motor neurone. Neurogenic changes were regularly found in the muscles of patients with myasthenia, even without muscular atrophy. The finding of these changes is no reason to reject the diagnosis. It is postulated that denervation occurs at the neuromuscular junction as a result of permanent absence of acetylcholine.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4708458      PMCID: PMC1083560          DOI: 10.1136/jnnp.36.2.244

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  26 in total

1.  DENERVATION OF MUSCLE IN MYASTHENIA GRAVIS. ROPORT OF A PATIENT WITH MYASTHENIA GRAVIS FOR 47 YEARS AND HISTOCHEMICAL SIGNS OF DENERVATION.

Authors:  I A BRODY; W K ENGEL
Journal:  Arch Neurol       Date:  1964-10

2.  Myasthenic syndrome with associated neuropathy. Report of a case, including response to curare therapy.

Authors:  R M STEIDL; A J OSWALD; F J KOTTKE
Journal:  Arch Neurol       Date:  1962-06

3.  The changes in the motor end-plate in myasthenia gravis.

Authors:  V MACDERMOT
Journal:  Brain       Date:  1960-03       Impact factor: 13.501

4.  Thymectomy during respiratory failure in a case of myopathy with myasthenia gravis.

Authors:  S G GRIFFIN; F J NATTRASS; E A PASK
Journal:  Lancet       Date:  1956-10-06       Impact factor: 79.321

5.  [Clinical and histological types of polymyosites].

Authors:  C COERS
Journal:  Rev Belg Pathol Med Exp       Date:  1956-09

6.  Prostigmine-responsiveness and the diagnosis of myasthenia gravis.

Authors:  L P ROWLAND
Journal:  Neurology       Date:  1955-09       Impact factor: 9.910

7.  [Myasthenia with atrophies of the myopathic type].

Authors:  A HOSOTTE
Journal:  Presse Med       Date:  1951-09-01       Impact factor: 1.228

8.  [Neurogenic muscular atrophies, manifested during a predominantly ocular myasthenia gravis].

Authors:  H C Hopf; H P Ludin
Journal:  Nervenarzt       Date:  1968-09       Impact factor: 1.214

9.  The histographic analysis of human muscle biopsies with regard to fiber types. 1. Adult male and female.

Authors:  M H Brooke; W K Engel
Journal:  Neurology       Date:  1969-03       Impact factor: 9.910

10.  [Myasthenic syndrome with progressive muscular dystrophy].

Authors:  A STRUPPLER
Journal:  Nervenarzt       Date:  1955-09-20       Impact factor: 1.214

View more
  15 in total

1.  Neuromuscular transmission in myasthenic single motor units.

Authors:  H A Kadrie; W F Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-03       Impact factor: 10.154

2.  Computer method for the analysis of evoked motor unit potentials. I. Control subjects and patients with myasthenia gravis.

Authors:  J P Ballantyne; S Hansen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-11       Impact factor: 10.154

3.  Lymphocyte stimulation by acetylcholine receptor in polymyositis.

Authors:  B M Conti-Tronconi; M Morgutti; M G Albizzati; F Clementi
Journal:  J Neurol       Date:  1978-03-09       Impact factor: 4.849

4.  The ocular signs and symptoms of myasthenia gravis.

Authors:  H J Oosterhuis
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

5.  Electrical and mechanical responses in the platysma and in the adductor pollicis muscle: in patients with myasthenia gravis.

Authors:  C Krarup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-03       Impact factor: 10.154

6.  Alternating myasthenia and myastheniform syndrome in the same subject.

Authors:  A Boiardi; G Bussone; S Negri
Journal:  J Neurol       Date:  1979-01-30       Impact factor: 4.849

7.  A new method for the estimation of the number of motor units in a muscle. I. Control subjects and patients with myasthenia gravis.

Authors:  J P Ballantyne; S Hansen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-08       Impact factor: 10.154

8.  Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.

Authors:  Zhiguo Li; Minshu Li; Kristofer Wood; Steffan Hettwer; Suraj A Muley; Fu-Dong Shi; Qiang Liu; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2018-01-08       Impact factor: 3.217

9.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

10.  The natural course of myasthenia gravis: a long term follow up study.

Authors:  H J Oosterhuis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.